Business Wire

NTT

25.7.2022 14:02:12 CEST | Business Wire | Press release

Share
NTT to Study Hydrogen Transportation Through Existing Pipelines

NTT Anode Energy Corporation (President and CEO: Teruyuki Kishimoto, Head Office: Minato-ku, Tokyo, NTT Anode Energy) announced a joint research and development project to study safety measures for the mass transportation of hydrogen through existing pipeline infrastructure. The study, being performed in collaboration with the National Institute of Advanced Industrial Science and Technology (President: Kazuhiko Ishimura, Chiyoda-ku, Tokyo AIST) and Toyota Tsusho Co., Ltd. (Representative Director: Ichiro Kashitani, Minato-ku, Tokyo, Toyota Tsusho), is expected to contribute to the realization of a pipeline transportation model for hydrogen that could be implemented globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005285/en/

According to a paper published by the International Renewable Energy Agency , “Hydrogen has emerged as an important part of the clean energy mix needed to ensure a sustainable future.” However, the large-scale, stable transportation of hydrogen through new pipeline infrastructure faces issues including land acquisition construction costs and building time. Utilizing existing pipeline infrastructure can solve these issues, and this new study represents the next step in this model’s proof-of-concept process.

The study will examine a double-piping system in which a hydrogen pipeline is placed in an existing pipe (the “sheath pipe”) buried underground. Factors to be measured and contributed to the formulation of technical standards include:

  1. On-site investigation of hydrogen leakage detection
  2. Verification of detection of signs of abnormality
  3. Establishment of a control sequence to ensure safety
  4. Performance evaluation of various hydrogen sensors in a real-world environment

Safety measures will be investigated under the assumption of unsteady conditions including rupture accidents and natural disasters during pipeline operation. In addition to examining the safety measures necessary for such use of existing pipelines, the study will verify the profitability of such projects, including cost analysis of transportation; energy input; and economic efficiency, as compared to other hydrogen transportation means.

Based on the knowledge and data gained through this project, NTT Anode Energy and its collaborators will promote and establish technical studies on safety measures for practical use. Ultimately, the project will also support the future supply of hydrogen to urban areas (e.g., public and commercial facilities, data centers and communications buildings; fuel cell vehicles; hydrogen stations, etc.), supply through pipelines utilizing communication pipelines (e.g., cable tunnels) and will contribute to the development of smart cities and the establishment of hydrogen supply means through pipelines in regions with a view to a society that consumes a large amount of hydrogen through the development of CO2-free hydrogen.

This project is being conducted in accordance with the "Research and development for the full-scale popularization of ultra-high pressure hydrogen infrastructure/Research and development for international development, international standardization, etc./Research and study for the examination of technical standards for hydrogen supply infrastructure, etc." of the New Energy and Industrial Technology Development Organization .

Primary Areas of Research by Collaborator

NTT Anode Energy

  • Hydrogen leakage detection;
  • Abnormal sign detection;
  • Hydrogen sensors investigation;
  • Investigation of residual hydrogen concentration at the time of hydrogen leakage; and
  • Investigation of explosion effect of manhole cover

AIST

  • Investigation of fire flame behavior caused by the ignition of leaked hydrogen in a simulated double piping system

Toyota Tsusho

  • Clarification of unit costs through verification of equipment, installation and safety costs; and
  • Verification of advantageous conditions and business establishment requirements of pipeline transportation

About NTT Anode Energy Group

As a company focused on leveraging the information communications technology and DC power supply technologies of the NTT Group in pursuit of “smart energy” business opportunities, NTT Anode Energy is working to develop and deliver energy solutions that make more sophisticated and efficient use of distributed energy resources such as renewable power generation facilities and storage batteries. In this way, it can fully express the unique synergies of the NTT Group. Through these efforts, we aim to work with partner companies to create new energy distribution mechanisms to help to revitalize industries and shape a more sustainable society.

NTT and the NTT logo are registered trademarks or trademarks of NIPPON TELEGRAPH AND TELEPHONE CORPORATION and/or its affiliates. All other referenced product names are trademarks of their respective owners. © 2022 NIPPON TELEGRAPH AND TELEPHONE CORPORATION

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye